Have Jade Biosciences insiders bought shares recently?

No open-market purchase by an insider of Jade Biosciences was filed in the last 90 days. The latest on record was on May 19, 2025.

How often do Jade Biosciences insiders buy and sell shares?

Since 2021, Jade Biosciences insiders reported 8 open-market purchases and 194 sales on Forms 4 and 5, with purchases in 3 different years, most recently 2025.

Who is selling Jade Biosciences stock?

No open-market sale by an insider of Jade Biosciences (JBIO) was filed with the SEC in the last 90 days.

Do members of Congress trade JBIO?

No trade in Jade Biosciences (JBIO) was disclosed by a member of Congress in the last 12 months.

Where does this data come from?

From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.

Jade Biosciences (JBIO) insider trading and stock trades

Q: When does Jade Biosciences report its next results?

Jade Biosciences's next results are expected on Mar 4, 2027, after the market closes. The date can move until the company confirms it. Insiders often trade in the weeks right after results.

OQRO

Ask OQRO about this page

Ask

Want the short version?

Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.

Explain this page What did insiders at JBIO buy and sell in the last 90 days?Which members of Congress and which funds traded JBIO recently?

Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.

JBIO price and disclosed activity

+66.7% (+$6.46) from Nov 13, 2025 to Nov 13, 2026 · adjusted daily closes

13F holdings, by quarter end

Insider and Congress marks sit on the trade date stated in the filing; solid is a purchase, hollow a sale. A number means several trades too close to tell apart at this range: pick a shorter range or open it for the list. Fund 13F reports are quarter-end snapshots filed up to 45 days later, so they are shown under the chart across the quarter they describe, not on the price line. Congress amounts are official ranges; mark size uses the lower bound. Past moves are not a forecast.

Insider open-market trades, filed in the last 90 daysNoneNo open-market trades reportedInsider trades →Congress trades, disclosed in the last 90 daysNoneNo House or Senate report names this stockCongress →Fund 13F changes, quarter ending Jun 30, 20261 added · 1 cut2 followed funds; holdings as of the quarter end, filed by Aug 14, 2026Fund moves →Federal contracts starting in the last 12 monthsNoneNo award found for this companyContracts →

Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.

Pharmaceutical Preparations company based in Waltham, Ma.

Last 12 months

+66.7%

S&P 500 +12.3% over the same dates

Market value

$1.03B

Close of Nov 13, 2026 × shares outstanding (per ADS where it applies)

S&P 500 +12.3% over the same dates. Prices adjusted for splits and dividends.

Short interest: 10.4M shares sold short (16.3% of shares outstanding), −7.5% vs the previous count, 14.1 days of normal trading to buy them back. FINRA, as of Oct 30, 2026.

The last year in context

Trading desk

Against the S&P 500 over the year

JBIO +64.7%S&P 500 fund (SPY) +10.4%

Since Nov 11, 2025, JBIO is up 64.7% and the index fund is up 10.4%: 54 points ahead of the market. Traders call a stock that beats the index over a period a relative-strength leader.

How much JBIO moves

A usual day: ±2.3%Half of the sessions moved less than this, half moved more.
Daily range (ATR 14): 5.9%Average distance between the low and the high of a session, over the last 14.
Largest one-day fall: −15.6%Apr 29, 2026
Largest one-day rise: +17.7%Nov 17, 2025
Deepest fall of the year: −50.1%From the close of Apr 27, 2026 to Oct 6, 2026.
Days of 5% or more: 54Out of 252 sessions, in either direction.

End-of-day prices. These figures describe the past year and say nothing about what comes next.

On the public record for Jade Biosciences over the 12 months to Nov 14, 2026: 2 clinical trials.

Latest results: quarter ending Jun 30, 2026

Revenue

—

Free cash flow, last 12 months

—

Cash from operations minus capital spending

Net debt

—

Debt —, cash $107M, at Jun 30, 2026

Net income, last 12 months

−$153M

From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Nov 13, 2026.

Insider buying and selling since 2021

Insiders of Jade Biosciences reported 8 open-market purchases and 194 sales since 2021; purchases in 3 different years, most recently 2025.

Year	Bought	Sold
2025	$44K1×1 trade	—
2024	$1.55M1×1 trade	$6.53M52×52 trades
2023	—	$5.47M61×61 trades
2022	—	$5.75M81×81 trades
2021	$71M6×6 trades	—

Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.

When insiders usually buy

Last results

Nov 13, 2026

Within the 30 days after it, until Dec 13, 2026

Next results, expected

Mar 4, 2027

after the market closes; the date can move until the company confirms it

Purchases after results

Not enough history

From Jade Biosciences's own results filings (8-K Item 2.02) and its insiders' Forms 4 and 5. Many companies only let insiders trade in a period after results; OQRO does not know Jade Biosciences's policy and only shows the pattern in the filings. A purchase made long after results, at a company whose insiders usually buy right after them, is marked “Bought outside the usual window”.

Holders above 5%

Anyone owning more than 5% must file within days. Structured filings have existed since December 2024, so older stakes that were never amended may be missing.

Late-stage clinical trials

1 active phase 3 trial and 1 active phase 2 trial led by this company, mostly in iga nephropathy, iga nephropathy (igan). The ones with the nearest registered primary completion date still ahead:

Source: ClinicalTrials.gov, studies whose lead sponsor is the company or a listed subsidiary. “Primary completion” is the sponsor's own registry date for the last main data collection. It is not an approval date, it says nothing about the result, and it is often revised.

Latest

See everything

Fund moves

13G stake

6.0%Stake

Filed 2w ago

A Schedule 13G is filed by holders above 5% who say they will not try to influence the company. Index funds and large asset managers file most of them.

More Official record

Fund moves

Want the short version?

Jade Biosciences

How this filing works

Insiders who traded Jade Biosciences

Other Pharmaceutical Preparations companies

JBIO price and disclosed activity

The last year in context

Latest results: quarter ending Jun 30, 2026

Insider buying and selling since 2021

When insiders usually buy

Holders above 5%

Late-stage clinical trials

Latest

6.0%Stake

2.86MShares reported

3.06MShares reported · -444K vs prior quarter

3.5MShares reported · +160K vs prior quarter

3.34MShares reported

Questions about Jade Biosciences insider trading

Insider buying and selling since 2021

The last year in context

Holders above 5%

Late-stage clinical trials

When insiders usually buy